Sökning: WFRF:(Lang Johannes) >
No Improvement of S...
No Improvement of Survival for Alveolar Rhabdomyosarcoma Patients After HLA-Matched Versus -Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Compared to Standard-of-Care Therapy
-
- Schober, Sebastian Johannes (författare)
- Tech Univ Munich, Childrens Canc Res Ctr, Sch Med, Dept Pediat, Munich, Germany.
-
- Hallmen, Erika (författare)
- Olga Hosp, Stuttgart Canc Ctr, Zent Kinder, Klinikum Landeshauptstadt Stuttgart gKAoR,Padiatri, Stuttgart, Germany.
-
- Ressle, Florian (författare)
- Tech Univ Munich, Childrens Canc Res Ctr, Sch Med, Dept Pediat, Munich, Germany.
-
visa fler...
-
- Gassmann, Hendrik (författare)
- Tech Univ Munich, Childrens Canc Res Ctr, Sch Med, Dept Pediat, Munich, Germany.
-
- Prexler, Carolin (författare)
- Tech Univ Munich, Childrens Canc Res Ctr, Sch Med, Dept Pediat, Munich, Germany.
-
- Wawer, Angela (författare)
- Tech Univ Munich, Childrens Canc Res Ctr, Sch Med, Dept Pediat, Munich, Germany.
-
- von Luettichau, Irene (författare)
- Tech Univ Munich, Childrens Canc Res Ctr, Sch Med, Dept Pediat, Munich, Germany.
-
- Ladenstein, Ruth (författare)
- Med Univ, St Anna Childrens Hosp, Childrens Canc Res Inst, Dept Pediat, Vienna, Austria.
-
- Kazanowska, Bernarda (författare)
- Wroclaw Med Univ, Dept Pediat Hematol Oncol, BMT, Wroclaw, Poland.
-
- Ljungman, Gustaf, 1958- (författare)
- Uppsala universitet,Barnonkologisk forskning - särskilt fokus på komplikationer
-
- Niggli, Felix (författare)
- Univ Hosp Zurich, Pediat Hematol & Oncol, Fac Med & Hlth Technol, Tampere Ctr Child Adolescent & Maternal Hlth Res, Zurich, Switzerland.
-
Lohi, Olli (författare)
-
- Hauer, Julia (författare)
- Tech Univ Munich, Childrens Canc Res Ctr, Sch Med, Dept Pediat, Munich, Germany.
-
- Gruhn, Bernd (författare)
- Jena Univ Hosp, Dept Pediat, Jena, Germany.
-
- Klingebiel, Thomas (författare)
- Universitatsklinikum Frankfurt, Dept Pediat Hematol & Oncol, Frankfurt, Germany.
-
- Bader, Peter (författare)
- Universitatsklinikum Frankfurt, Dept Pediat Hematol & Oncol, Frankfurt, Germany.
-
- Burdach, Stefan (författare)
- Tech Univ Munich, Inst Pathol, Sch Med, Munich, Germany.
-
- Lang, Peter (författare)
- Universitatsklinikum Tubingen, Dept Pediat Hematol & Oncol, Tubingen, Germany.
-
- Sparber-Sauer, Monika (författare)
- Olga Hosp, Stuttgart Canc Ctr, Zent Kinder, Klinikum Landeshauptstadt Stuttgart gKAoR,Padiatri, Stuttgart, Germany.;Med Fak Univ Tubingen, Tubingen, Germany.
-
- Koscielniak, Ewa (författare)
- Olga Hosp, Stuttgart Canc Ctr, Zent Kinder, Klinikum Landeshauptstadt Stuttgart gKAoR,Padiatri, Stuttgart, Germany.;Med Fak Univ Tubingen, Tubingen, Germany.
-
- Thiel, Uwe (författare)
- Tech Univ Munich, Childrens Canc Res Ctr, Sch Med, Dept Pediat, Munich, Germany.
-
visa färre...
-
Tech Univ Munich, Childrens Canc Res Ctr, Sch Med, Dept Pediat, Munich, Germany Olga Hosp, Stuttgart Canc Ctr, Zent Kinder, Klinikum Landeshauptstadt Stuttgart gKAoR,Padiatri, Stuttgart, Germany. (creator_code:org_t)
- 2022-05-10
- 2022
- Engelska.
-
Ingår i: Frontiers in Oncology. - : Frontiers Media S.A.. - 2234-943X. ; 12
- Relaterad länk:
-
https://doi.org/10.3...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.3...
-
visa färre...
Abstract
Ämnesord
Stäng
- BackgroundPatients with stage IV alveolar rhabdomyosarcoma (RMA) have a 5-year-survival rate not exceeding 30%. Here, we assess the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for these patients in comparison to standard-of-care regimens. We also compare the use of HLA-mismatched vs. HLA-matched grafts after reduced vs. myeloablative conditioning regimens, respectively. Patients and MethodsIn this retrospective analysis, we compare event-free survival (EFS), overall survival (OS), and toxicity of HLA-mismatched vs. -matched transplanted patients in uni- and multivariate analyses (total: n = 50, HLA-matched: n = 15, HLA-mismatched: n = 35). Here, the factors age at diagnosis, age at allo-HSCT, sex, Oberlin score, disease status at allo-HSCT, and HLA graft type are assessed. For 29 primarily transplanted patients, three matched non-transplanted patients per one transplanted patient were identified from the CWS registry. Outcomes were respectively compared for OS and EFS. Matching criteria included sex, age at diagnosis, favorable/unfavorable primary tumor site, and metastatic sites. ResultsMedian EFS and OS did not differ significantly between HLA-mismatched and -matched patients. In the mismatched group, incidence of acute GvHD was 0.87 (grade III-IV: 0.14) vs. 0.80 in HLA-matched patients (grade III-IV: 0.20). Transplant-related mortality (TRM) of all patients was 0.20 and did not differ significantly between HLA-mismatched and -matched groups. A proportion of 0.58 relapsed or progressed and died of disease (HLA-mismatched: 0.66, HLA-matched: 0.53) whereas 0.18 were alive in complete remission (CR) at data collection. Multivariate and competing risk analyses confirmed CR and very good partial response (VGPR) status prior to allo-HSCT as the only decisive predictor for OS (p < 0.001). Matched-pair survival analyses of primarily transplanted patients vs. matched non-transplanted patients also identified disease status prior to allo-HSCT (CR, VGPR) as the only significant predictor for EFS. Here, OS was not affected, however. ConclusionIn this retrospective analysis, only a subgroup of patients with good response at allo-HSCT survived. There was no survival benefit of allo-transplanted patients compared to matched controls, suggesting the absence of a clinically relevant graft-versus-RMA effect in the current setting. The results of this analysis do not support further implementation of allo-HSCT in RMA stage IV patients.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Nyckelord
- allogeneic stem cell transplantation
- haploidentical
- high-risk rhabdomyosarcoma
- alveolar rhabdomyosarcoma (RMA) stage IV
- matched-pair analysis
- graft-versus-host disease
- transplant-related mortality
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Schober, Sebasti ...
-
Hallmen, Erika
-
Ressle, Florian
-
Gassmann, Hendri ...
-
Prexler, Carolin
-
Wawer, Angela
-
visa fler...
-
von Luettichau, ...
-
Ladenstein, Ruth
-
Kazanowska, Bern ...
-
Ljungman, Gustaf ...
-
Niggli, Felix
-
Lohi, Olli
-
Hauer, Julia
-
Gruhn, Bernd
-
Klingebiel, Thom ...
-
Bader, Peter
-
Burdach, Stefan
-
Lang, Peter
-
Sparber-Sauer, M ...
-
Koscielniak, Ewa
-
Thiel, Uwe
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
- Artiklar i publikationen
-
Frontiers in Onc ...
- Av lärosätet
-
Uppsala universitet